Dr. Catriona Jamieson Announced as Inaugural Chief of New Division of Regenerative Medicine

Announced today by Wolfgang H. Dillmann, MD, Helen M. Ranney Distinguished Professor and Chair of the Department of Medicine

Catriona H. M. Jamieson, MD, PhD

Catriona Jamieson, MD, PhD

Please join me in officially welcoming Catriona Jamieson, MD, PhD, as the inaugural chief of the new Division of Regenerative Medicine. The Department of Medicine is delighted to announce the inception of the Division of Regenerative Medicine and we enthusiastically support Dr. Jamieson’s talent and vision for this innovative endeavor.

Wolfgang H. Dillmann, MD

Wolfgang H. Dillmann, MD

Dr. Jamieson joined the UC San Diego faculty in 2005 and is an associate professor of Medicine in the Division of Hematology-Oncology. She has proven her leadership skills, expertise and effectiveness in her current positions as director of the Stem Cell Research Program at Moores Cancer Center, co-leader of the Hematologic Malignancies Program, hematology team leader, co-director of the UC San Diego Stem Cell Training Grant, coordinating course director of the Interdisciplinary Stem Cell course, and a co-director of the new Sanford Stem Cell Clinical Center.

Dr. Jamieson received her medical and doctorate degrees from the University of British Columbia. She completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as her postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford.

As a physician-scientist, Dr. Jamieson specializes in leukemia and myeloproliferative neoplasms, which are a family of uncommon, but not rare, degenerative disorders in which the body overproduces blood cells. These disorders can cause blood clotting which can lead to heart attack, stroke, and other life-threatening complications including transformation to acute leukemia. Dr. Jamieson’s research focuses on the mutant stem cells and progenitor cells in myeloproliferative neoplasms, which can give rise to cancer stem cells. Her stem-cell research studies have taken a substantial leap from identifying a promising treatment in the laboratory to completing the first clinical trial targeting cancer stem cells in humans. Her discoveries in myeloproliferative neoplasms are now being brought together with a drug development track of a regional pharmaceutical company.

Please join me in giving your enthusiastic support to Dr. Jamieson in her new leadership role as the inaugural chief of the Division of Regenerative Medicine here at UC San Diego. This is a unique and exciting opportunity to make UC San Diego a key hub for the rapid translation of stem cell discoveries to the clinic.

$100 Million Gift Launches Sanford Stem Cell Clinical Center

UC San Diego-based effort will speed discoveries to new drugs and treatments for patients

Dr. Catriona Jamieson

In a bold and singular step toward delivering the therapeutic promise of human stem cells, businessman and philanthropist T. Denny Sanford has committed $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego… Read the full story from the UC San Diego News Center

Pictured: Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

UC Medical Campus Consortium Named Designated Center to Translate Innovations into Improved Health

A consortium of the five University of California medical campuses at UC San Diego, UC Davis, UC Irvine, UCLA and UC San Francisco has been designated a Center for Accelerated Innovations by the National Heart, Lung and Blood Institute (NHLBI). The designation, among the first of its kind from NHLBI, recognizes the University of California’s potential to translate its leading-edge discoveries into innovative products that benefit patients. … Read the full story from the UCSD Newsroom


Dr. Gary FiresteinGary S. Firestein, MD, chair of the UC BRAID consortium that will oversee the new UC Center for Accelerated Innovations, is dean and associate vice chancellor of translational medicine at UC San Diego Health Sciences

He led UC San Diego’s successful effort to win a Clinical and Translational Science Award in 2010 and is the founding director of the UC San Diego Clinical and Translational Research Institute.

Firestein is professor of medicine and former chief of the Division of Rheumatology, Allergy & Immunology at UC San Diego. He served as division chief from 1998 until he stepped down in 2010 to devote full time to his activities as dean of translational medicine.

In 2011, philanthropists Lisa and Steve Altman made a major gift to the planned Clinical and Translational Research building on the La Jolla campus of UC San Diego Health System. Construction started in early 2013 and the building, named the Altman Clinical and Translational Research Institute, is scheduled to open in 2016.

UC San Diego Health System Video: The Altman Clinical and Translational Research Institute

More Information:

New Understanding of ‘Copper Pump’ in Cells Could Prime Discovery of Anti-Cancer Drugs

A team of University of California, San Diego researchers has made new discoveries about a copper-transporting protein in the membranes of human cells that drug-discovery scientists can co-opt for the development of new anti-cancer drugs…. Read the full story from the UCSD Newsroom


Dr. Stephen Howell
Stephen B. Howell, MD, was on the research team, which was led by Igor Tsigelny of the Department of Neurosciences and the San Diego Supercomputer Center. Dr. Howell is professor of medicine in the Division of Hematology-Oncology and a translational researcher at the UC San Diego Moores Cancer Center, where he is associate director for clinical research.

He also directs the Cancer Therapeutics Training Program (CT2) and co-leads, with Dr. David Cheresh, the Tumor Growth, Invasion and Metastasis Program.Read the study report in Cell Biochemistry and Biophysics

Karl Y. Hostetler, MD, Receives Prestigious 2012 Gertrude Elion Memorial Award

Karl Y. Hostetler, MD, has been selected as the recipient of the 2012 Gertrude Elion Memorial Lecture Award by the International Society of Antiviral Research. Hostetler is a professor of medicine in the Divisions of Infectious Diseases and Endocrinology at the UC San Diego School of Medicine. Each year the award is given to a scientist of international repute who has made significant contributions to the field of antiviral research and to mentoring of young scientists…. Read the full story from the UCSD Newsroom


Dr. Karl Hostetler
More about Dr. Hostetler and his work:

Breaking Ground on a New Era of Health Care

Jacobs Medical Center to transform world-class research into top-quality clinical care

Philanthropists, community leaders, health care visionaries, architects and contractors, along with faculty and staff of UC San Diego, gathered April 9 to celebrate the official start of construction for the Jacobs Medical Center, a ten-story, multi-specialty medical center that will open in La Jolla in 2016. The new medical center will transform the delivery of health care by ensuring that medical research discoveries are quickly translated into enhanced patient care…. Read the full story from the UCSD Newsroom

More news about the Jacobs Medical Center:

A New Approach to Faster Anticancer Drug Discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of SciencesRead the full story from the UCSD Newsroom

M. Geoff Rosenfeld, MD,
M. Geoff Rosenfeld, MD, is an investigator in the study. Dr. Rosenfeld is professor of medicine in the Division of Endocrinology and Metabolism and a Howard Hughes Medical Institute investigator. |  Read the article in the Proceedings of the National Academy of Sciences.

CTRI Receives $37.2 Million Clinical and Translational Science Award

A 5-year, $37.2 million grant award for the Clinical and Translational Research Institute (CTRI) is the subject of the UCSD Newsroom story, “UC San Diego Receives Major Clinical and Translational Science Award.”

Dr. Gary Firestein, Director of the CTRI, is principal investigator of the project. Dr. Firestein is Dean of Translational Medicine for UC San Diego Health Sciences and Professor of Medicine in the Division of Rheumatology, Allergy and Immunology.